Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 5.0 | 4.0 |
Min SIP Amount | ₹500 | ₹500 |
Expense Ratio | 1.93 | 2.26 |
NAV | ₹424.48 | ₹287.25 |
Fund Started | 04 Jun 1999 | 01 Aug 2005 |
Fund Size | ₹4130.76 Cr | ₹1126.13 Cr |
Exit Load | Exit load of 0.50% if redeemed within 15 days | Exit load of 1% if redeemed within 30 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -1.71% | -1.23% |
3 Year | 23.41% | 23.83% |
5 Year | 17.27% | 15.73% |
1 Year
3 Year
5 Year
Equity | 96.05% | 98.75% |
Cash | 3.88% | 1.24% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.18% |
Divi's Laboratories Ltd. | 7.26% |
Max Healthcare Institute Ltd. | 5.62% |
Cipla Ltd. | 4.41% |
Lonza Group Ag | 4.05% |
Lupin Ltd. | 4.04% |
Acutaas Chemicals Ltd. | 3.81% |
Fortis Healthcare Ltd. | 3.76% |
Torrent Pharmaceuticals Ltd. | 3.49% |
Jupiter Life Line Hospitals Ltd. | 3.46% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 9.76% |
Ajanta Pharma Ltd. | 6.48% |
Lupin Ltd. | 5.91% |
Glenmark Pharmaceuticals Ltd. | 4.06% |
Dr. Reddy's Laboratories Ltd. | 3.74% |
Gland Pharma Ltd. | 3.46% |
Apollo Hospitals Enterprise Ltd. | 3.45% |
Alkem Laboratories Ltd. | 3.43% |
Procter & Gamble Health Ltd. | 3.41% |
Cipla Ltd. | 3.40% |
Name | Tanmaya Desai | Kamal Gada |
Start Date | 17 May 2024 | 02 May 2022 |
Name
Start Date
Description | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. |
Launch Date | 04 Jun 1999 | 01 Aug 2005 |
Description
Launch Date